Anthem Biosciences IPO Allotment Status: Here's What Investors Should Know After 67.42x Subscription
By Shishta Dutta | Updated at: Jul 17, 2025 12:56 PM IST
Bangalore, July 17, 2025 – Anthem Biosciences’ ₹3,395 crore IPO closed on July 16 with overwhelming demand, drawing a total subscription of 67.42 times. Investors are now awaiting the allotment status, which is expected to be released later today by the registrar, KFin Technologies.
Anthem Biosciences IPO saw robust interest across all categories, with QIBs subscribing 192.80x and retail investors 5.98x. Backed by strong institutional participation and demand for Contract Research, Development and Manufacturing Organization (CRDMO) firms, the IPO reflected high confidence in Anthem’s integrated R&D model and global client portfolio.
How to Check Anthem Biosciences IPO Allotment Status
Via KFin Technologies (Registrar):
- Visit: https://ris.kfintech.com/ipostatus
- Select Anthem Biosciences Limited from the list
- Enter PAN, Application Number, or DP/Client ID
- Complete the Captcha and click Submit
Via BSE Website:
- Go to: https://www.bseindia.com/investors/appli_check.aspx
- Select Equity and choose Anthem Biosciences Ltd
- Enter Application Number and PAN
- Click Search
Note: Only applications with UPI mandate status as RC100 (“Mandate Accepted and Amount Blocked”) are eligible for allotment.
Final Subscription Snapshot (As on July 16, 2025 – 5:00 PM IST)
| Category | Shares Offered | Shares Bid For | Subscription (x) |
|---|---|---|---|
| Qualified Institutional Buyers (QIBs) | 1,18,83,334 | 2,29,10,95,976 | 192.80 |
| Non-Institutional Investors (NIIs) | 89,12,500 | 39,84,26,912 | 44.70 |
| Retail Individual Investors (RIIs) | 2,07,95,833 | 12,42,99,214 | 5.98 |
| Employee Reservation | 1,58,654 | 11,08,692 | 6.99 |
| Total | 4,17,50,321 | 2,81,49,30,794 | 67.42 |
What Are the Chances of Getting an Allotment?
The chances of receiving an allotment depend entirely on the investor category, number of applications, and allotment methodology.
For Retail Individual Investors (RIIs):
- The retail category was subscribed 5.98 times, meaning roughly 1 out of every 5 to 6 applicants may receive an allotment, assuming one lot per investor and uniform distribution.
- Allotment is done through a lottery system in over-subscribed retail issues.
- Those who applied for a single lot stand the same chance as those who applied for more.
For Non-Institutional Investors (NIIs):
- The NII portion was oversubscribed 44.70x, with high-value bids (above ₹10 lakh) at 51.66x and mid-tier bids (₹2–10 lakh) at 30.82x.
- Allotment is made on a proportionate basis. Investors in this category are likely to receive only a small fraction of what they applied for.
For Employees:
- The employee quota saw 6.99x subscription. Chances here are also lower but slightly better compared to retail, as the pool of applicants is limited.
For QIBs:
- Though oversubscribed by 192.80x, allotment to QIBs is discretionary and based on anchor and institutional bookbuilding norms. Allocations are typically made in consultation with merchant bankers.
What’s Next?
| Event | Date |
|---|---|
| Allotment Finalization | July 17, 2025 |
| Refunds Begin | July 18, 2025 |
| Shares Credited to Demat | July 18, 2025 |
| Listing on Stock Exchanges | July 21, 2025 |
Allotment results will be available on the websites of KFin Technologies and BSE once released. Investors are advised to check these platforms using their PAN or application details to confirm whether they’ve secured allotment.
Outlook
Strong oversubscription across investor segments highlights high institutional confidence in Anthem’s CRDMO capabilities. Market participants will now track listing price performance and post-listing volume. Sustained demand and sectoral tailwinds will be key drivers for potential upside in the near term.
About the Company
Anthem Biosciences Limited, based in Bengaluru, is a prominent Contract Research, Development and Manufacturing Organization (CRDMO), offering end-to-end services across drug discovery, clinical development, and commercial manufacturing. The company serves clients globally and operates across five technology platforms: RNAi, ADCs, peptides, lipids, and oligonucleotides. Anthem’s robust growth, deep scientific expertise, and fully integrated infrastructure make it a leading player in India’s life sciences innovation ecosystem.
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
